Satsuma Pharmaceuticals is a biotechnology business based in the US. Satsuma Pharmaceuticals shares (STSA) are listed on the NASDAQ and all prices are listed in US Dollars. Satsuma Pharmaceuticals employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Satsuma Pharmaceuticals stock
How to buy Satsuma Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – STSA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Satsuma Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Satsuma Pharmaceuticals stock price (NASDAQ: STSA)
Use our graph to track the performance of STSA stocks over time.Satsuma Pharmaceuticals shares at a glance
Latest market close | $1.10 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $0.99 |
200-day moving average | $2.18 |
Wall St. target price | $2.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.99 |
Is it a good time to buy Satsuma Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Satsuma Pharmaceuticals price performance over time
Historical closes compared with the close of $1.1 from 2023-06-07
1 week (2024-08-25) | N/A |
---|---|
1 month (2024-08-01) | N/A |
3 months (2024-06-01) | N/A |
6 months (2024-03-01) | N/A |
1 year (2023-09-01) | N/A |
---|---|
2 years (2022-09-02) | -84.26% |
3 years (2021-09-03) | 5.07 |
5 years (2019-09-01) | N/A |
Satsuma Pharmaceuticals financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -49.62% |
Return on equity TTM | -104.04% |
Profit margin | 0% |
Book value | $1.14 |
Market Capitalization | $36.8 million |
TTM: trailing 12 months
Satsuma Pharmaceuticals share dividends
We're not expecting Satsuma Pharmaceuticals to pay a dividend over the next 12 months.
Satsuma Pharmaceuticals share price volatility
Over the last 12 months, Satsuma Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Satsuma Pharmaceuticals's is 0.1018. This would suggest that Satsuma Pharmaceuticals's shares are less volatile than average (for this exchange).
Satsuma Pharmaceuticals overview
Satsuma Pharmaceuticals, Inc. , a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
Frequently asked questions
What percentage of Satsuma Pharmaceuticals is owned by insiders or institutions?Currently 10.429% of Satsuma Pharmaceuticals shares are held by insiders and 57.901% by institutions. How many people work for Satsuma Pharmaceuticals?
Latest data suggests 25 work at Satsuma Pharmaceuticals. When does the fiscal year end for Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals's fiscal year ends in December. Where is Satsuma Pharmaceuticals based?
Satsuma Pharmaceuticals's address is: 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Satsuma Pharmaceuticals's ISIN number?
Satsuma Pharmaceuticals's international securities identification number is: US80405P1075 What is Satsuma Pharmaceuticals's CUSIP number?
Satsuma Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 80405P107
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question